| Full Name | Sarah Criddle |
|---|---|
| Gender | Female |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | 593 Eddy St, Providence, Rhode Island |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306422217 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Criddle, MD 593 Eddy St, Providence, RI 02903-4923 Ph: () - | Sarah Criddle, MD 593 Eddy St, Providence, RI 02903 Ph: (401) 444-4030 |
News Archive
Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, announced today the grant of US Patent 7,682,783 and US Patent 7,682,784 entitled "Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics". The USPTO awarded the patents to Metabolon on March 23, 2010. The issued claims in the new patents are for uses of metabolomics to identify diagnostic biomarkers for depression and schizophrenia by profiling classes of metabolites in a sample.
UT Southwestern Medical Center is one of a handful of top research institutions evaluating a promising new medication researchers hope can reduce the severity and frequency of asthma attacks in inner-city children, a population known to have a high prevalence of severe asthma.
The angiographic outcomes of patients in the Cerecyte Coil Trial add to evidence that "bioactive" coils are no better than bare platinum coils in patients with cerebral aneurysms.
Many age-related neurological diseases are associated with defective proteins accumulating in nerve cells, suggesting that the cell's normal disposal mechanisms are not operating correctly.
› Verified 2 days ago